What is the overall financial health of McKesson Corporation based on this filing?

McKesson Corporation shows a strong financial performance trend, with significant increases in revenue and net income for the quarter and six months ended September 30, 2002. The company is effectively managing its operating segments, particularly Pharmaceutical Solutions, and has strategically invested in growth areas like Information Solutions through acquisitions. While there are ongoing restructuring costs and legal matters, the core business appears robust, supported by improved operating profits and a healthy cash flow from operations.

What were the key drivers of revenue growth?

Revenue growth was primarily driven by the Pharmaceutical Solutions segment, which accounts for over 92% of consolidated revenues. This growth was fueled by increases in U.S. healthcare revenues (driven by market growth, increased drug utilization, price increases, and new business agreements) and international pharmaceutical revenues. The Information Solutions segment also contributed positively due to growth in software, services, hardware, and the recent acquisition of A.L.I. Technologies.

How did the company manage its debt and liquidity during this period?

McKesson utilized short-term borrowings of $282.0 million by September 30, 2002, to support commercial paper and fund acquisitions, leading to an increase in its debt-to-capital ratio. The company also has significant revolving credit facilities in place to support its working capital needs. While liquidity was impacted by increased borrowings and use of cash for acquisitions, the company expects to meet future debt maturities and cash requirements through existing cash, operations, and credit sources.

Are there any significant ongoing legal or restructuring issues that investors should be aware of?

Yes, McKesson is involved in ongoing securities litigation related to past accounting improprieties at HBOC, the outcome of which is uncertain and could materially impact financial results. Additionally, the company incurred restructuring charges and credits related to operational adjustments and distribution center consolidations, particularly within the Medical-Surgical Solutions segment. While these indicate ongoing efforts to streamline operations, they also represent costs and potential impacts on financial performance.

MCK 10-Q Quarterly Report Q2 FY2003 — Revenue, Net Income, EPS

Summary

McKesson Corporation's (MCK) 10-Q filing for the period ending September 29, 2002, demonstrates a strong rebound in financial performance, driven by significant revenue growth across its segments, particularly in Pharmaceutical Solutions. The company reported increased net income and diluted earnings per share for both the quarter and the six-month period compared to the prior year. This improvement is attributed to a combination of market growth, strategic business initiatives, and effective cost management. Despite some ongoing challenges, such as restructuring costs and legal proceedings, the company appears to be on a solid footing, with a healthy increase in operating profit and positive cash flow from operations. Key financial indicators show robust top-line growth and improved profitability. The balance sheet reflects increased assets, largely due to acquisitions and goodwill, while liabilities have also risen, partly due to short-term borrowings. The company has actively managed its capital structure and liquidity through credit facilities and is focused on strategic investments, such as the acquisition of A.L.I. Technologies, to enhance its service offerings and market position. Investors can take note of the company's strategic focus on expanding its Information Solutions segment and the ongoing efforts to streamline its operations.

Key Highlights

1Revenue increased by 13% to $13.69 billion for the quarter and 15% to $27.31 billion for the six months ended September 30, 2002, driven primarily by the Pharmaceutical Solutions segment.
2Net income for the quarter rose to $124.8 million, a 58% increase year-over-year, with diluted EPS at $0.42, up 56%. For the six-month period, net income was $242.1 million, up 31%, with diluted EPS at $0.82.
3The company acquired A.L.I. Technologies Inc. for $349.2 million in July 2002 to enhance its Information Solutions segment with digital medical imaging capabilities.
4Operating profit increased significantly by 38% to $264.8 million for the quarter and 38% to $520.5 million for the six months, reflecting strong performance across segments, especially Pharmaceutical Solutions and Information Solutions.
5The balance sheet shows an increase in Total Assets to $13.87 billion from $13.32 billion, with a notable rise in Goodwill and Other Intangibles due to acquisitions.
6Short-term borrowings increased to $282.0 million at September 30, 2002, primarily to support commercial paper and finance acquisitions, while cash and equivalents decreased.
7The company is managing restructuring charges and credits, with a net credit of $6.7 million pre-tax for the quarter and a net charge of $5.6 million pre-tax for the six months, reflecting ongoing operational adjustments.

MCKESSON CORP Quarterly Report for Q2 Ended Sep 30, 2002

Summary

Key Highlights

Frequently Asked Questions